Brief: Calliditas Therapeutics Granted Orphan Drug Designation By FDA For Treatment Of Alport Syndrome With Setanaxib
27/09/2023 18:42
Sept 27 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CALLIDITAS THERAPEUTICS GRANTED ORPHAN DRUG DESIGNATION BY
THE
FDA FOR THE TREATMENT OF ALPORT SYNDROME WITH SETANAXIB
* CALLIDITAS THERAPEUTICS- PLANS TO INITIATE RANDOMIZED,
PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY IN ALPORT SYNDROME
WITH AROUND 20 PATIENTS IN Q4 2023
Source text for Eikon: ID:nPn3DFt24a
Further company coverage: CALTX.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations